The Company has two reportable segments, the Global Pharmaceuticals Division (generic products & services) and the Impax Pharmaceuticals Division (brand products & services) and does not allocate general corporate services to either segment.
Global Pharmaceuticals Division Information
|(unaudited, amounts in thousands)||
Three Months Ended
Six Months Ended
|Global product sales, net||$||126,435||$||111,125||$||242,646||$||203,463|
|Cost of revenues||70,478||63,257||133,584||110,431|
|Research and development||12,136||13,466||22,798||23,242|
|Selling, general and administrative||3,319||2,579||7,692||5,198|
|Total operating expenses||18,369||18,254||37,442||32,423|
|Income from operations||$||44,221||$||39,048||$||85,307||$||81,053|
Global Pharmaceuticals Division revenues in the second quarter 2012 were $133.1 million, up 10% compared to the prior year period, due to higher Global product sales, net, partially offset by lower Rx Partner sales.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts